Lisa Harding, MD, says ECT, ketamine, TMS, and VNS can work, but evidence on what comes after acute response remains thin.
|Articles|May 19, 2010
- Psychiatric Times Vol 27 No 5
- Volume 27
- Issue 5
Get the Bigger Therapeutic Picture
Advertisement
- Cochrane Central Register of Controlled Trials (CENTRAL) is a bibliographical database of controlled trials. This is an important resource because using MEDLINE alone will not yield all possible reports of controlled trials.
http://uscc.cochrane.org/en/newPage3.html . Accessed March 24, 2010.
- MedWatch is the FDA safety information and adverse reporting program.
http://www.fda.gov/safety/MedWatch/default.htm . Accessed March 24, 2010.
- The Carlat Psychiatry Report is a monthly newsletter that provides clinically relevant, unbiased information on psychiatric practice and psychotropic medications and openly discusses alternatives to psychopharmacological treatment.
http://www.thecarlatreport.com . Accessed March 24, 2010.
- PharmedOut is a physician-run project funded through the Attorney General Consumer and Prescriber Education grant program that “empowers physicians to identify and counter inappropriate pharmaceutical promotion practices. PharmedOut promotes evidence-based medicine by providing news, resources, and links to pharma-free CME courses.”
http://www.pharmedout.org . Accessed March 24, 2010.
Articles in this issue
over 16 years ago
Ethical Aspects of Self-Disclosure in Psychotherapyover 16 years ago
Introduction: Ethical Dilemmas Old and Newover 16 years ago
Undue Pharmaceutical Influence on Psychiatric Practiceover 16 years ago
A Psychiatrist’s Guitar Poemover 16 years ago
DSM5 and the Medicalization of Grief: Two Perspectivesover 16 years ago
Extraordinarily Ordinaryover 16 years ago
The Political Diagnosis: Psychiatry in the Service of the Lawover 16 years ago
The Fort Hood Aftermath-Army Accountability Review and Psychiatristsover 16 years ago
Memory Reconsolidation and What Albert Ellis Knew All AlongAdvertisement
Related to this article
Why D2 blockade alone falls short in schizophrenia, and what neurotransmitter, genetic and neuroimaging research means for treatment-resistant patients.
Discover expanded psychiatry coverage with new podcasts, interactive digital issues, and event reporting—we are your always-on media hub delivering fresh insights year-round.
GLP-1 drugs enter psychiatry, curbing antipsychotic weight gain while raising new questions about addiction, mood, eating disorders, and culture.
Miss Golden Corner 2026 discusses the South Carolina campus naloxone law she helped start and her push to reduce addiction stigma in rural communities.
Explore the urgent legal, ethical, and clinical challenges in emergency psychiatry, share cases and tips, and contribute to Psychiatric Times’ November series.
A Delphi panel recommends screening for eating disorders before GLP-1 receptor agonist initiation.
Alkermes launches a phase 2 trial of oral orexin-2 agonist ALKS 7290 to boost antidepressant response in major depressive disorder, assessing safety and symptom relief.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Ozempic Dilemma: Promises and Pitfalls in Psychiatry
2
Schizophrenia: A Telltale of the Brain’s Complexity
3
Podcast: Interventional Psychiatry and the Challenge of Difficult-to-Treat Depression
4
Talking With Titans: Sheldon Preskorn, MD, on the Evolution of Psychopharmacology
5